TRAUMA SURGERY



Extramedullary versus intramedullary fixation of stable trochanteric femoral fractures: a systematic review and meta-analysis

Miliaan L. Zeelenberg¹ · Leendert H. T. Nugteren¹ · A. Cornelis Plaisier¹ · Sverre A. I. Loggers^{1,2} · Pieter Joosse² · Dennis Den Hartog¹ · Michael H. J. Verhofstad¹ · Esther M. M. van Lieshout¹ · STABLE-HIP Study Group

Received: 18 January 2023 / Accepted: 19 April 2023 $\ensuremath{\mathbb{O}}$ The Author(s) 2023

Abstract

Objective This systematic review and meta-analysis compared extramedullary fixation and intramedullary fixation for stable two-part trochanteric femoral fractures (AO type 31-A1) with regards to functional outcomes, complications, and surgical outcomes.

Methods Embase, Medline, Web of Science, Cochrane Central Register of Controlled Trials, and Google Scholar were searched for randomized controlled trials (RCTs) and observational studies. Effect estimates were pooled across studies using random effects models. Results were presented as weighted risk ratio (RR) or weighted mean difference (MD) with corresponding 95% confidence interval (95% CI).

Results Five RCTs (397 patients) and 14 observational studies (21,396 patients) were included. No significant differences in functional outcomes, complications, or surgical outcomes were found between extramedullary and intramedullary fixation devices, except for a difference in duration of surgery (MD 14.1 min, CI 5.76–22.33, p < 0.001) and intra-operative blood loss (MD 92.30 mL, CI 13.49–171.12, p = 0.02), favoring intramedullary fixation.

Conclusion Current literature shows no meaningful differences in complications, surgical, or functional outcomes between extramedullary and intramedullary fixation of stable two-part trochanteric femoral fractures. Both treatment options result in good outcomes. This study implicates that, costs should be taken into account when considering implants or comparing fixation methods in future research.

Keywords Trochanteric · Hip fracture · Intramedullary · Extramedullary · AO type 31-A1

Miliaan L. Zeelenberg and Leendert H. T. Nugteren have contributed equally.

Michael H. J. Verhofstad and Esther M. M. van Lieshout have contributed equally.

STABLE-HIP Study Group members are listed in the Acknowledgements section.

Esther M. M. van Lieshout e.vanlieshout@erasmusmc.nl

¹ Trauma Research Unit, Department of Surgery, Erasmus MC, University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands

² Department of Surgery, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands

Introduction

Proximal femoral fractures are one of the most common types of fracture in the elderly population worldwide with a global incidence of over 182.5 per 100,000 person-years [1-3]. The total annual medical costs associated with proximal femoral fractures are over \$50,000 per patient in the U.S or over \notin 20,000 in the Netherlands [4, 5]. Due to an aging population and increased life expectancy worldwide, the burden of these fractures on health care systems is increasing. About half of proximal femoral fractures are trochanteric fractures (AO type 31-A1, A2, or A3) [3]. These can be divided in stable two-part fractures (AO type 31-A1) and unstable fractures (AO type 31-A2 and A3) [6]. Of these fractures, type 31-A1 fractures make up 36% [7].

Various studies suggest that intramedullary fixation is the most appropriate approach for treatment of unstable fractures [8-10]. For stable fractures, the implant of choice remains a topic of debate. A plethora of fixation devices for both intramedullary and extramedullary fixation is available and high variability in implant preference exists between countries, hospitals, and even individual surgeons [11].

The use of intramedullary fixation devices in both stable and unstable trochanteric fractures has risen in recent years [12, 13]. Less than 2 decades ago, intramedullary fixation was discouraged as older reviews reported higher risks of revision, reoperation, and other complications [10, 14–16]. However, recent studies, that directly compared extramedullary and intramedullary fixation of stable two-part trochanteric fractures and a review of AO type A1-A3 trochanteric fractures reported none to minor differences favoring one of the two fixation types [17-21]. Due to an increased experience, development of new devices, and abolition of devices of lower quality with inferior results, the presentday intramedullary devices result in better results and are no longer inferior to extramedullary devices [22]. However, superiority over extramedullary devices has never been proven.

Therefore, current surgical guidelines, such as the Dutch Guideline for treatment of proximal femoral fractures and United Kingdom's NICE (National Institute for Health and Care Excellence) guideline, state that due to a lack of difference in effectiveness between extramedullary and intramedullary fixation, the device with the lowest costs (i.e., a sliding hip screw) is preferred [23, 24]. The optimal and most cost-effective treatment remains a topic of debate and the steep increase in the use of intramedullary fixation may be influenced by other factors than only clinical data on complications or outcomes, such as individual preference, training, or geographical differences [12, 25].

As no extensive systematic review and meta-analysis of the literature has been conducted on treatment of, exclusively, stable two-part trochanteric fractures, the aim of this study was to compare extramedullary versus intramedullary fixation for stable two-part trochanteric femoral fractures (AO type 31-A1) only using present-day devices.

Methods

This systematic review and meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guideline [26]. A protocol was developed prior to conducting the current study.

Search strategy and selection criteria

Embase, Pubmed/Medline, Web of Science databases, and the Cochrane Central Register of Controlled Trials (CENTRAL) were initially searched on 22 March 2021 for studies comparing extramedullary and intramedullary fixation of AO type trochanteric fractures. The initial search was updated on 26 September 2022. Online Resource 1 shows the search string used and the search results. After deduplication, two reviewers (LHTN and ACP) independently screened titles and abstracts for eligibility for inclusion. Any disagreement was resolved by consensus. The same two reviewers subsequently conducted the full-text screening of eligible articles.

Studies were included when they presented data (a) published after 1990 of (b) acute (c) AO-OTA 31-A1 trochanteric fractures, (d) comparing intramedullary and extramedullary fixation (e) in patients > 50 years, (f) using currently available devices (an overview of included devices per study is provided in Online Resource 2). Studies were excluded when they (a) presented no original data, (b) did not mention relevant outcomes (e.g. only incidence of fixation with specific devices), (c) were biomechanical, in vitro or cadaveric studies, (d) pathological fractures, (e) bilateral fractures, (f) periprosthetic fractures, (g) were case reports, or (h) did not make distinction between type of fracture or treatment.

Data extraction

All baseline characteristics were independently extracted by two reviewers (LHTN and ACP) using a predefined data extraction sheet and included: first author, publication year, setting, study design, study period, follow-up time, total study population, and study population with type 31-A1 fracture. In addition, patient characteristics were collected including age, sex, implant type, and number of patients treated using extramedullary or intramedullary fixation.

Data were collected for the following outcome measures: functional outcomes: Harris hip score, pain, parker mobility score, and walking ability (cases of unassisted/good walking ability were compared with assisted or no walking ability). Complications: reoperation, non-union, cut-out, peri-implant fracture, conversion to prosthesis, implant/ fixation failure, superficial and deep infection, malunion, limb-length discrepancy, heterotopic ossification, osteolysis in fixed implants, and mortality. Surgical outcomes/operation characteristics: operation time, blood loss, bone-healing time, quality of reduction, hospital stay, fluoroscopy time, and costs/cost-effectiveness. All outcomes were included as defined by individual presenting articles.

If case data were not described sufficiently in the full-text or supplementary materials, the authors were contacted by e-mail once. If this approach was unsuccessful, missing data were imputed based on the average standard deviation for the total included population across all studies with no missing data and adjusted for population size. This was done for the standard deviations of Harris hip score in Sevinc et al. [27], the standard deviations of 1-year pain scores by Matre et al. [28], and standard deviations for bone-healing time by Cho et al. [29].

Quality assessment

Two reviewers (LHTN and ACP) independently assessed the methodological quality of all included studies using the risk of bias 2 (RoB 2) tool for assessing risk of bias in randomized trials and MINORS, a methodological index for non-randomized studies [30, 31]. Disagreement was resolved by consensus. The RoB 2 is structured into a fixed set of domains of bias, trial design, conduct, and reporting. Within each domain, a series of signaling questions indicate features that are relevant to risk of bias. A proposed judgement about the risk of bias for each domain is generated by an algorithm, based on the signaling questions. Judgement can be 'Low' or 'High' risk of bias, or can express 'Some concerns'. The MINORS ranges from 0 (poor quality) to 24 (high quality).

Statistical analysis

Data were analyzed using Review Manager (Revman, version 5.3.5). Input in the analysis was sample size, mean, and standard deviation (SD) for continuous outcomes and sample size and number of cases with the specific outcome for binary outcomes. Random effects models were used for measuring treatment effects because of the expected heterogeneity due the inclusion of both RCT and observational studies and comparison of multiple types of devices in different countries and clinical settings. No (age-)adjusted analyses were performed, all data were analyzed as described in the original studies. Treatment effects of the binary outcome measures were pooled using the Cochran-Mantel-Haenszel statistic and are presented as risk ratio (RR) with 95% confidence intervals (CI). Treatment effects of the continuous outcome measures were pooled using the inverse variance weighting method and are presented as mean difference (MD) or standardized mean difference (SMD) with 95% confidence intervals (CI). SMD was used when included studies used different measurement scales for the same variable. All analyses were stratified on study design (randomized controlled trials (RCTs) or observational studies) and were presented as Forest plots. Differences between pooled estimates for the two types of study design were compared using the χ^2 -test test. Heterogeneity between studies was assessed qualitatively using the Cochran's O-test and quantified using the I^2 statistic. Statistical significance was assumed using a p value threshold of 0.05. Publication bias was assessed by visual inspection of funnel plots for all studied variables (Online Resource 3).

Results

Search

The literature search and selection of included studies is shown in Fig. 1. The primary search resulted in 14,577 records. After deduplication, 7,213 records were screened on title and abstract. Out of the 473 articles assessed for eligibility, a total of 19 studies (five RCTs [17, 32–35] and 14 observational studies [18, 19, 27–29, 36–44]) were included in the final analysis. All studies were published between 2005 and 2022.

Baseline study characteristics

The 19 included studies (Table 1) comprised a total of 21,793 patients. The RCTs included a total of 397 patients and the observational studies a total of 21,396 patients. Extramedullary fixation was used in 15,910 patients and 5,883 patients were treated using intramedullary fixation. The follow-up ranged from 6 to 60 months. A complete overview of reported variables per study is shown in Table 2.

Quality assessment

The details and distribution of the quality assessment using the RoB 2 for RCTs and MINORS for observational studies are described in Tables 3 and 4. The overall bias assessment in the RoB 2 ranged from high overall risk of bias in Pajarinen et al. [32] to low overall risk of bias in Tao et al. [35] and Ovesen et al. [33]. The mean score for the MINORS was 18 (SD 2.5) and ranged from 15 (moderate quality) to 22 (high quality).

A summary of all study results and meta-analyses is provided in Table 5. The most (clinically) relevant and statistically significant outcome measures are described below. Forrest plots for additional outcome measures can be found in Online Resource 4 (OR4).

Functional outcomes

Harris hip score (HHS)

The mean HHS (six studies, Fig. 2) at a minimum of 1 year after trauma was 82.2 in 261 patients for extramedullary fixation and 82.9 in 249 patients for intramedullary fixation. There was no significant difference between groups, with a considerable level of heterogeneity of effect across




Fig. 1 Flowchart of search results, article inclusion and exclusion

studies (MD 1.38, CI – 3.43 to 6.18, $I^2 = 92\%$, p = 0.57) [19, 27, 35, 38, 39, 41].

Pain

The mean 1-year post-operative pain score (four studies, Fig. 3) was 2.4 in 2679 patients for extramedullary fixation and 2.2 in 1006 patients for intramedullary fixation, on a 10-point scale. There was no significant difference in standardized 1-year post-operative pain between groups (SMD 0.04, CI – 0.04 to 0.11, $I^2 = 0\%$, p = 0.36) [17, 28, 40, 42].

Other functional outcomes

No significant difference between groups was found in Parker mobility score (MD 0.52, CI – 0.11 to 1.14, $I^2 = 0\%$, p = 0.11) (Online resource 4, Fig. 1) [18, 41] and 1-year post-operative walking ability (RR 1.11, CI 0.82–1.50, $I^2 = 0\%$, p = 0.97) (OR4, Fig. 2) [35, 39].

frac
Ξ
4
31
é
O type
ō
Ā
n in A
u
ξ
ха
'n,
ar)
ulli
ц
ne
ar
xt
sus extram
ŝ
era
>
ĥ
Ш
qn
ne
car
nti
. <u>-</u> -
.Е
ar
đ
õ
s
lie
ğ
ls.
<u>Sec</u>
n
<u>1</u> 2
Ē
ō
θW
-12
verv
ó
-
-

Study (publica- Country	Country	Study	Inclusion	Total	Extramedul	Extramedullary fixation			Intramedu	Intramedullary fixation			Follow-up
tion date)		design	period	population AO type 31-A1 fracture	Number of Device patients	Device	Male (%)	Mean age (years)	Num- ber of patients	Device	Male (%)	Mean age (years)	(months)
RCTs													
Ovesen et al. (2006) [33]	Denmark	RCT	2001– 2003	40	17	SHQ	40.4 ^ª	78.5 ^a	23	GN	79.9 ^a	37.7 ^a	12
Pajarinen et al. (2005) [32]	Finland	RCT	1999– 2001	47	26	SHQ	25.9 ^a	80.3 ^a	21	PFN	80.9ª	24.9 ^a	4
Parker et al. (2017) [17]	UK	RCT	2002– 2009	170	83	SHS	23.2 ^ª	82.1 ^a	87	TPF+TPFT	82.2 ^a	22.4 ^a	12
Tao et al. (2013) [35]	China	RCT	2010– 2011	19	6	Reverse LISS	60.09	80.3	10	PFNA	80.1	22.2	12
Zou et al. Chin (2009) [34] Observational studies	China	RCT	2006– 2007	121	63	SHQ	24	65	58	PFNA	65	21	12
Alessio- Mazzola et al. (2022) [41]	Italy	Retrospec- tive cohort	2015– 2019	85	4	SHQ	20.5	83.7	41	NFA	14.6	86.6	41.6°
Andruszkow et al. (2012) [36]	Germany	Retrospec- tive cohort	2007– 2010	106	101	SHQ	29.8 ^{a,b}	80.8 ^{a,b}	5	GN	80.8 ^{a,b}	29.8 ^{a,b}	N.D
Cho et al. (2016) [29]	South Korea	Retrospec- tive cohort	2004– 2014	194	113	SHQ	38.1	84.2	81	PFNA	81	32.1	25
Crespo et al. (2012) [37]	Spain	Retrospec- tive cohort with follow- up	2004– 2009	179	125	PCCP	26.7 ^a	82.5 ^a	54	Ng	83.1 ^a	18.4 ^ª	12
Grønhaug et al. (2022) [42]	Norway	Prospec- tive cohort	2013– 2019	6,841	4,811	SHS	32	83.0	2,030	IMN	69	83.0	36
Matre et al. (2013) [28]	Norway	Retrospec- tive cohort	2005- 2010	7,643	6,355	DHS + ACHS	29	82	1,288	GN + PFNA + TITAN	82	27	22
Mohan et al. (2019) [18]	India	Retrospec- tive cohort	2017– 2018	53	23	SHQ	67	45	30	PFN	60	60	9

		-		Ē	t L					•			:
Study (publica- Country	Country	Study	Inclusion	Total		Extramedullary fixation			Intramedu	Intramedullary fixation			Follow-up
tion date)		design	period	population AO type 31-A1 fracture	Number of Device patients	f Device	Male (%)	Male (%) Mean age (years)	Num- ber of patients	Device	Male (%)	Male (%) Mean age (years)	(months)
Pehlivanoğlu et al. (2021) [43]	Turkey	Retrospec- tive cohort	2005– 2013	122	65	SHQ	47.7	72	57	PFN	38.8	74.7	DHS 54.7° PFN 44.2°
Pyrhönen et al. (2022) [44]	Sweden	Retrospec- tive cohort	2012– 2018	5,460	3,733	SHS	36.1	84	1,727	IMN	31.0	85	60
Sevinç et al. (2020) [27]	Turkey	Prospec- tive cohort	N.D	104	48	SHQ	59.1 ^a	77.1 ^a	56	PFNA	78.9ª	48.2 ^a	12
Talmaç et al. (2019) [19]	Turkey	Retrospec- tive cohort	2011– 2016	203	68+62	DHS + PCCP	52.5	70.9	73	PFNA	73.9	44.4	12
Tian et al. (2010) [39]	China	Retrospec- tive cohort	2013– 2017	58	20	SHQ	40.0	70.4	38	PFNA	73.1	68.4	24
Van der Sijp et al. (2021) [40]	The Neth- erlands	Prospec- tive cohort	2016– 2018	126	32	SHQ	28.1	81.3	94	PFNA	80.9	24.2	12
Yu et al. (2016) [38]	China	Retrospec- tive cohort	2005– 2015	222	112	DHS	50.9	73.1	110	PFNA	72.0	46.3	48-60

sion plating. *PFN* proximal femoral nail, *PFNA* proximal femoral nail antirotation, *Reverse LISS* reverse less invasive stabilization system, *SHS* sliding hip screw, *TTAN* Trigen intertan trochan-teric antegrade nail, *TPF* Targon proximal femoral nail, *TPFT* Targon proximal femoral telescrew nail

^aValue for total study population including AO type 31-A2 and/or A3 fractures

^bValue for individual groups not specified in study

^cMean follow-up, minimum of 12 months

 $\overline{\textcircled{D}}$ Springer

Table 2 (continued)	ontinued)																			
Outcome	Corre- sponding figure	Ales- sio- Maz- zola et al. [41]	Andrusz- kow et al. [36]	Cho et al. [29]	Cre- spo et al. [37]	Grøna- hug et al. [42]	Matre et al. [28]	Mohan et al. [18]	Ovesen et al. [33]	Pajarinen et al. [32]	Parker et al. [17]	Pehlivanoğlu et al. [43]	Pyrhönen et al. [44]	Sevinç Ta et al. m [27] et [1	Tal- T maç et et al. [3 [19]	Tao Ti et al. et [35] [3	Tian Van et al. der [39] Sijp et al. [40]	n Yu : et al. p [38] al.	Zou l. et al.] [34]	
Mal- union	OR4-5	+	I	I	I	I	I	I	I	I	I	1	I	+			I	+	I	
Limb- length discrep- ancy	OR4-6	I	I	+	I	I	I	I	I	I	I	1	I	+	1	1	I	+	I	
Het- erotopic ossifi- cation	OR4-7	+	I	I	I	I	I	I	I	I	I	1	1	+	1		I	+	I	
Osteoly- sis	OR4-8	I	I	I	I	I	I	I	I	I	I	I	I	+	і	I	Ι	+	I	
Mortality	OR4-9	I	I	I	I	Ι	I	I	I	I	I	I	I	+	1		+	I	I	
Surgery duration	10	+	I	+	I	I	+	+	I	I	I	+	I	+	+	+	+	I	I	
Blood loss	Ξ	I	I	+	I	I	I	+	I	I	I	+	I	+	+	+	+	I	I	
Bone healing time	OR4-10	I	I	+	I	I	I	I	I	I	I	I	I	+	+	+	I	+	I	
Qual- ity of reduc- tion	OR4-11	+	I	I	I	I	I	I	I	I	I	I	I	+	+	1	+	+	I	
Hospital stay	OR4-12	+	I	I	I	I	I	I	I	I	I	+	I	+	+	+	۱	I	I	
Fluoros- copy time	OR4-13	+	I	I	I	I	I	I	I	I	I	I	I	+	+	1	I	I	I	
+ outcome	e measure r	eported	+ outcome measure reported in study, - outcome measure not reported in study, OR4 online resource 4	outcom	e measi	ure not rel	ported in	study, Oh	24 online 1	esource 4										

Table 3 Quality assessment ofincluded RCTs using the RoB2 criteria

Study	D1	D2	D3	D4	D5	Overall
Ovesen et al. (2006) [33]	+	+	+	+	•	+
Pajarinen et al. (2005) [32]	+		!	+	+	-
Parker et al. (2017) [17]	+	+	!	+	+	!
Tao et al. (2013) [35]	+	+	+	+	+	+
Zou et al. (2009) [34]	!	+	+	!	•	!

+ Low risk of bias; ! Some concern of bias; - High risk of bias.

D1: Randomization process; D2: Deviations from the intended interventions; D3: Missing outcome data; D4: Measurement of the outcome; D5: Selection of the reported result.

+ low risk of bias, ! some concern of bias, - high risk of bias, D1 randomization process, D2 deviations from the intended interventions, D3 missing outcome data, D4 measurement of the outcome, D5 selection of the reported result

Complications

Reoperation

Reoperation (11 studies, Fig. 4) was performed in 483 out of 15,389 (3.1%) in extramedullary fixation and 199 out of 5548 (3.6%) patients in intramedullary fixation. No significant difference between groups was found, with a moderate level of heterogeneity of effect across studies (RR 0.94, 0.72–1.23, l^2 =34%, p=0.85) [17, 19, 28, 33, 34, 38–42, 44].

Nonunion

Nonunion (nine studies, Fig. 5) occurred in 26 cases out of 6933 (0.4%) in extramedullary fixation and seven cases out of 1790 (0.4%) in intramedullary fixation. There was no significant difference in non-union between groups (RR 1.41, CI 0.58–3.42, $I^2 = 0\%$, p=0.45 [17–19, 28, 29, 34, 38, 39, 41].

Cut-out

Cut-out (12 studies, Fig. 6) occurred in 36 cases out of 7158 (0.5%) in extramedullary fixation and 20 cases out of 1852 (1.1%) in intramedullary fixation. There was no significant difference in cut-out rate between groups (RR 0.69, CI 0.40–1.20, $I^2 = 0\%$, p = 0.19) [17–19, 28, 29, 32–34, 36–39].

Peri-implant fracture

Peri-implant fracture (five studies, Fig. 7) occurred in 16 cases out of 6732 (0.2%) in extramedullary fixation and 7 cases out of 1600 (0.4%) in intramedullary fixation. There was no significant difference in peri-implant fracture rate

between fixation groups, with a moderate to substantial level of heterogeneity of effect across studies (RR 1.14, CI 0.16–8.18, I^2 =66%, p=0.89) [17, 19, 28, 34, 38].

Conversion to prosthesis

Conversion to prosthesis (eight studies, Fig. 8) occurred in 269 cases out 15,118 (1.8%) in extramedullary fixation and 105 cases out of 5282 (2.0%) in intramedullary fixation. There was no significant difference between groups (RR 0.87, CI 0.66–1.15, $l^2 = 15\%$, p = 0.32) [17, 28, 29, 33, 39, 41, 42, 44].

Implant/fixation failure

Implant or fixation failure (eight studies, Fig. 9) was reported in 70 cases out of 6858 (1.0%) in extramedullary fixation and 15 cases out of 1767 (0.8%) in intramedullary fixation. There was no significant difference between groups (RR 1.78, CI 0.82-3.86, $I^2 = 20\%$, p = 0.15) [19, 28, 29, 34, 38–41].

Other complications

There were no significant differences between groups in deep infection (RR 2.39, CI 0.47–12.25, $I^2 = 0\%$, p = 0.30, OR4, Fig. 3) [18, 29, 32–34, 38, 39, 41], superficial infection (RR 1.12, CI 0.43–2.90, $I^2 = 0\%$, p = 0.81, OR4, Fig. 4) [19, 29, 32, 34, 38, 39, 41, 43], malunion (RR 0.78, CI 0.33–1.84, $I^2 = 0\%$, p = 0.58, OR4, Fig. 5) [19, 38, 41], limb-length discrepancy > 25 mm (RR 3.36, CI 0.25–45.01, $I^2 = 48\%$, p = 0.36, OR4, Fig. 6) [19, 29, 38], heterotopic ossification (RR 0.76, CI 0.26–2.25, $I^2 = 23\%$, p = 0.62, OR4, Fig. 7) [19, 38, 41], osteolysis in well-fixed implants (RR 0.74, CI 0.05–11.03, $I^2 = 30\%$, p = 0.83, OR4, Fig. 8) [19, 38], and

Study	Aim	Aim Inclusion Collection	Collection	Endpoints	Assessment	Follow-up Loss of period follow-u	Loss of follow-up	Study size calculation	Control group	Contempo- rary group	Baseline equivalence	Statistics	Total
Alessio-Mazzola et al. [41]	2	2	2	1	1	2	1	1	2	2	2	2	20
Andruszkow et al. [36]	2	2	0	2	0	1	2	0	1	2	1	2	15
Crespo et al. [37]	1	2	0	2	0	2	1	0	2	2	1	2	15
Grønhaug et al. [42]	2	2	2	2	0	2	1	0	2	2	2	2	19
Sevinç et al. [27]	2	0	2	2	0	2	2	0	2	0	1	2	15
Cho et al. [29]	2	2	2	2	0	2	2	0	2	2	2	2	20
Matre et al. [28]	2	2	1	2	0	2	1	2	2	2	2	2	20
Mohan et al. [18]	2	1	0	2	0	1	2	0	2	2	1	2	15
Pehlivanoğlu et al. [43]	2	2	2	1	0	2	0	0	2	2	1	1	15
Pyrhönen et al. [44]	2	2	2	2	0	2	2	0	2	2	2	2	20
Talmaç et al. [19]	2	2	2	2	0	2	2	0	2	2	1	2	19
Tian et al. [39]	2	2	0	2	0	2	2	0	2	2	1	2	17
Van der Sijp et al. [40]	2	2	2	2	2	2	1	2	2	2	1	2	22
Yu et al. [38]	1	2	1	2	0	2	2	0	2	2	2	2	18
Total scores can range from 0 up to 24, with lower scores indicating higher risk of bias) up to 2	4, with lower	scores indicat	ing higher risł	k of bias								

0 not reported, 1 reported but inadequate, 2 reported and adequate

 Table 4
 Quality assessment of included observational studies using the MINORS criteria

Poster value R. I.I.I. Observational EM. National Minimican Minimican Contributed states Null 1 1 19 16 (-3); 7.1) 5 321 13 (-4)0, 68) 321 24 006 22 004 (-0)4(10, 1) 926 926 Null 1 19 16 (-3); 7.1) 5 322 13 (-4)0, 68) 324 006 22 004 (-0)4(10, 1) 926 926 Null 1 11 11 11 11 25 11 0.35 0.41 11 926						i			, i				:		
Nutlex Inductional Anoled value (95% CD) Statisty T Pooled value (95% CD) Statisty Distribution Statisty Distribution Statisty Distribution Statisty Distribution Distribution <thdistribution< th=""> Distribution <thdist< th=""><th>Outcome measure</th><th>Pooled value</th><th>RCTS</th><th></th><th></th><th>Observ</th><th>vational</th><th></th><th>EM fixai</th><th>tion</th><th>IM fix</th><th>ation</th><th>Combined studies</th><th></th><th></th></thdist<></thdistribution<>	Outcome measure	Pooled value	RCTS			Observ	vational		EM fixai	tion	IM fix	ation	Combined studies		
			Studies	и		Studie		Pooled value (95% CI)	и	Mean/cases	и	Mean/cases	Pooled value (95% CI)	l^2	<i>p</i> value
SMD 1 138 $0.2 < -0.2$, 0.5 3.547 $0.63 < -0.1; 0.1$ 2.57 $0.04 < -0.0; 0.1$ 0.6 ND x x x x x x x x x $0.2 < -0.1; 0.1$ 0.6 $0.2 < 0.2 < -0.1; 1.1$ 0.6 R 1 19 $1.1(0.8, 1.6)$ 1 57 $1.1(0.7; 1.8)$ 28 $19(687)$ 48 $28(587)$ $1.1(0.8, 1.6)$ 0.6 R 2 2.244 Noevens 2 $1.4(0.5; 4.3.)$ $0.94(0.7; 1.2)$ 13.38 0.966751 0.96757132 $14.066.3.4.3$ 0.674561 $0.90771.12$ 3.435 R 2 2.244 Noevens 5 $0.9607.122$ 15.118 $26.04.57$ $15.06.25.96$ $0.9077.122$ $13.66.25.92$ $0.677661.120$ $0.9777.122$ R 2 2.244 Noevens 5 $0.9607.1.25$ 15.118 $26.04.57$ $15.06.25.92$ $0.677.1.25$ $13.64.25$ $0.577.0.1.25$ $0.577.0.25.10.5$	Harris hip score (1 year)	MD		19	1.6 (-3.9; 7.1)	S	502	1.3 (-4.0; 6.8)	261	82.2	249	82.9	1.4 (-3.3; 6.1)	92%	0.57
i MID x	Pain score (1 year, 0–10 scale)	SMD	1	138		б	3547	0.03 (-0.1; 0.1)	2679	2.4	1006	2.2	0.04 (-0.04; 0.1)	%0	0.36
RR 1 19 1.1(0.8;16) 1 57 1.1(0.7;13) 28 19(68%) 48 28(58%) 1.1(0.8;16) 06 RR 3 304 1.1(0.2;8.0) 8 20,633 0.9(0.7;12) 15.380 433 (1.9) 56% 0.4(0.7;12) 346 RR 2 264 Noevens 7 849 1.4(0.6; 3.4) 0.93 26(1.%) 1790 7(0.4;7) 0.4 0.5 RR 2 264 Noevens 5 8668 1.1(0.2; 8.1) 0.9 0.7(0.4; 1.2) 1518 36(0.5%) 1790 7(0.4; 1.2) 0.9 RR 2 244 0.15 83 1.1(0.2; 8.1) 0.9 0.7 0.4 0.7 0.4 0.7 0.7 0.6% 0.7 0.6% 0.7 0.6% 0.7 0.6% 0.7 0.6% 0.7 0.6% 0.7 0.6% 0.7 0.6% 0.7 0.6% 0.7 0.6% 0.7 0.6% 0.7	Parker mobility score (1 year)	MD	x	×	х	5	114	0.52 (-0.1; 1.1)	54	6.9	60	6.2	0.52 (-0.1; 1.1)	%0	0.11
	Good walking ability (1 year)	RR	-	19	1.1 (0.8; 1.6)	-	57	$1.1 \ (0.7; 1.8)$	28	19 (68%)	48	28 (58%)	1.1 (0.8; 1.6)	%0	0.51
an RR 2 264 No crems 7 8439 14 (16.5.3.4) 6933 26 (0.4\%) 1790 7 (0.4\%) 14 (0.6.3.4) 0% RR 2 254 No crems 7 8439 0.7 (0.4; 1.2) 7158 56 (0.2\%) 137 (0.4; 1.2) 0.7 (0.4; 1.2) <t< td=""><td>Reoperation</td><td>RR</td><td>3</td><td>304</td><td></td><td>8</td><td>20,633</td><td>0.94 (0.7; 1.2)</td><td>15,389</td><td>483 (3.1%)</td><td>5548</td><td>199 (3.6%)</td><td>0.94 (0.7; 1.2)</td><td>34%</td><td>0.67</td></t<>	Reoperation	RR	3	304		8	20,633	0.94 (0.7; 1.2)	15,389	483 (3.1%)	5548	199 (3.6%)	0.94 (0.7; 1.2)	34%	0.67
RR 4 351 11 0.2 5.4 8.659 0.7 0.4 12 0.7 0.4 12 0.6 0.7 0.4 12 0.6	Non-union	RR	2	264		7	8459	$1.4 \ (0.6; \ 3.4)$	6933	26 (0.4%)	1790	7 (0.4%)	$1.4 \ (0.6; \ 3.4)$	%0	0.45
RR 2 264 No events 3 8068 $1.1(0.2; 8.2)$ 6732 1600 $7(0.4\%)$ $1.2(0.2; 8.2)$ 666 RR 2 264 No events 6 20.190 $0.9(0.7; 1.2)$ 15118 $269(1.8\%)$ 5282 $105(2.0\%)$ $0.9(0.7; 1.2)$ 15% 1505% $24(0.5; 1.23)$ 15% 1505% $24(0.5; 1.23)$ 15% 1505% $110(4.45)$ 1506 $7(0.4\%)$ $12(0.2; 8.2)$ 66% RR 3 7 No events 6 8341 $10(0.4; 1.23)$ 562 $9(1.6\%)$ 1767 $15(0.8, 4.5)$ 26% $11(0.4, 2.9)$ 05% RR x x x x x x x $24(0.3; 1.3)$ 562 $9(1.6\%)$ $10(4.2\%)$ $0.3(0.7; 1.2)$ 0.5% $0.5(0.2; 1.2)$ 0.5% $0.5(0.2; 1.2)$ 0.5% 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5	Cut-out	RR	4	351	1.1 (0.2; 5.4)	8	8659	0.7 (0.4; 1.2)	7158	36 (0.5%)	1852	20 (1.1%)	0.7 (0.4; 1.2)	0%	0.19
RR 2 264 No events 6 20.190 $0.9(0.7; 1.2)$ 15.118 $260(1.8\%)$ 5282 $105(2.0\%)$ $0.9(0.7; 1.2)$ 15.57 RR 1 94 $2.4(0.1; 58.3)$ 7 8531 $18(0.8; 4.5)$ 6858 $70(1.0\%)$ 1767 $15(0.85\%)$ $18(0.8, 4.5)$ 209 RR 2 141 $2.4(0.1; 58.3)$ 7 8874 $10(0.4; 5.123)$ 6688 $70(1.0\%)$ 1767 $15(0.85\%)$ $18(0.8, 4.5)$ 200 RR x x x 3 510 $0.8(0.3; 1.8)$ $24(0.5; 12.3)$ 24 $10(0.3\%)$ $24(0.3; 4.50)$ $24(0.3; 4.50)$ 24 $15(0.3\%)$ $24(0.3; 4.50)$ 26 RR x x x x x 2 $24(0.3; 4.50)$ 355 $11(3.1\%)$ $24(0.3; 4.50)$ $26(0.3; 2.3)$ $24(0.3; 4.50)$ 26 26 26 26 26 26 $10(3.5\%)$ 24 $10(3.5\%)$ 24 2	Peri-implant fracture	RR	2	264		б	8068	1.1 (0.2; 8.2)	6732	16 (0.2%)	1600	7 (0.4%)	1.2 (0.2; 8.2)	66%	0.89
RR 1 94 24 (0.1; 58.3) 7 8531 18 (0.8; 4.5) 6558 70 (1.0%) 1767 15 (0.85%) 18 (0.8-4.5) 20% RR 3 87 Noevents 6 707 2.4 (0.5; 12.3) 408 4 (1.0%) 386 1 (0.3%) 1.8 (0.8-4.5) 20% RR x x x x 3 510 0.8 (0.3; 1.8) 386 1 (0.3%) 24 (0.5; 12.3) 0% RR x x x 3 510 0.8 (0.3; 1.8) 386 1 (0.45%) 0.8 (0.3; 1.8) 0% RR x x 3 510 0.8 (0.3; 1.8) 286 10 (3.5%) 24 (0.5; 1.2.3) 0% RR x x x 3 510 0.8 (0.3; 1.8) 355 11 (0.45%) 0.8 (0.3; 1.8) 0% RR x x x 2 34 (0.3; 450) 355 10 (4.5%) 0.7 (0.5; 1.10) 0% RR x x	Conversion to pros- thesis	RR	2	264		9	20,190	0.9 (0.7; 1.2)	15,118	269 (1.8%)	5282	105 (2.0%)	0.9 (0.7; 1.2)	15%	0.32
RR 3 87 No events 6 707 24 (0.5; 12.3) 408 4(1.0\%) 366 1 (0.4; 2.9) 0% RR z 141 24 (0.1; 58.3) 6 884 1 0 (0.4; 2.8) 562 9 (1.6\%) 463 6 (1.3\%) 1 (0.4; 2.9) 0% RR x x x x x 3 510 0.8 (0.3; 1.8) 286 10 (3.5\%) 244 10 (4.4; 2.9) 0% RR x x x x x x 3 619 34 (0.3; 2.3) 286 10 (3.5\%) 24 10 (4.5; 0.3) 0% RR x	Implant/fixation failure	RR	1	94	2.4 (0.1; 58.3)	7	8531	$1.8\ (0.8; 4.5)$	6858	70 (1.0%)	1767	15 (0.85%)	1.8 (0.8-4.5)	20%	0.15
RR 2 141 24(0.1;58.3) 6 884 10(04;28) 562 9(1.6\%) 463 6(1.3\%) 1.1(04;29) 0% RR x x x x 3 510 08(0.3;1.8) 286 10(3.5\%) 224 10(4.5\%) 0.8(0.3;1.8) 0% RR x x x x x 3 510 0.8(0.3;1.8) 286 10(3.5\%) 224 10(4.5%) 0.8(0.3;1.8) 0% RR x x x x 3 510 0.7(0.05;11.0) 242 1(0.3\%) 264 1(0.3\%) 0.7(0.05;11.0) 243 RR x	Deep infection	RR	3	87	No events	9	707	2.4 (0.5; 12.3)	408	4 (1.0%)	386	1 (0.3%)	2.4 (0.5; 12.3)	0%	0.30
RR x	Superficial infection	RR	2	141	2.4 (0.1; 58.3)	9	884	1.0(0.4; 2.8)	562	9 (1.6%)	463	6(1.3%)	$1.1 \ (0.4; 2.9)$	0%	0.81
RR x	Malunion	RR	х	х	х	Э	510	$0.8\ (0.3;\ 1.8)$	286	10(3.5%)	224	10~(4.5%)	$0.8\ (0.3;1.8)$	%0	0.58
RR x	Limb-length discrep- ancy	RR	x	x	x	ŝ	619	3.4 (0.3; 45.0)	355	11 (3.1%)	264	1 (0.3%)	3.4 (0.3; 45.0)	42%	0.36
RR x	Heterotopic ossifica- tion	RR	x	x	х	б	510	0.76 (0.3; 2.3)	286	10 (3.5%)	224	3 (4.9%)	0.76 (0.3; 2.3)	23%	0.62
RR x x x z 329 1.0 (0.6; 1.6) 162 31 (19%) 167 30 (18%) 1.0 (0.6; 1.6) 0% MD 1 19 26 (17; 36) 8 8370 13 (5.4; 20) 6704 53.5 1685 53.2 14 (7; 21) 96% MD 1 19 23 (-34; 100) 6 641 103 (17; 189) 305 351 355 204 92 (17; 171) 98% MD 1 19 32 (0.2; 6.2) 4 599 $-0.4 (-1.4; 0.7)$ 334 17.2 284 16.9 $-0.04 (-1.1; 1.0)$ 84% MD 1 19 0.9 (0.7; 1.2) 4 558 1.04 (0.96; 1.1) 277 191 (71%) 300 176 (59%) 1.03 (1.0; 1.1) 0% MD 1 19 $0.9 (0.7; 1.2)$ 4 558 1.04 (1.56%) 300 176 (59%) 1.03 (1.0; 1.1) 0% MD 1 19 2.7 (-3.7; 9.1) 4 390	Osteolysis	RR	x	х	х	2	463	0.7 (0.05; 11.0)	242	1(0.4%)	183	1 (0.5%)	$0.7\ (0.05;11.0)$	0%	0.83
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	1-year mortality	RR	x	x	х	7	329	$1.0\ (0.6;\ 1.6)$	162	31 (19%)	167	30(18%)	$1.0\ (0.6;\ 1.6)$	0%	0.92
MD 1 19 $23 (-54; 100)$ 6 641 103 (17; 189) 305 351 355 204 92 (17; 171) 98% MD 1 19 $3.2 (0.2; 6.2)$ 4 599 $-0.4 (-1.4; 0.7)$ 334 17.2 284 16.9 $-0.04 (-1.1; 10)$ 84% RR 1 19 $0.9 (0.7; 1.2)$ 4 558 $1.04 (0.96; 1.1)$ 277 $191 (71\%)$ 300 $176 (59\%)$ $1.03 (1.0; 1.1)$ 0% MD 1 19 $2.7 (-3.7; 9.1)$ 4 558 $1.04 (0.96; 1.1)$ 277 $191 (71\%)$ 300 $176 (59\%)$ $1.03 (1.0; 1.1)$ 0% MD 1 19 $2.7 (-3.7; 9.1)$ 4 390 $0.48 (-0.3; 1.3)$ 218 7.9 191 $10.5 (-0.3; 1.3)$ $0.5 (-0.3; 1.3)$ 58% MD 1 19 $77 (-3.7; 9.1)$ 2 $210 (7.6, 0.3; 1.3)$ $218 (7.9, 0.3)$ $1.33 (5.0, 0.3; 1.3)$ $58\% (-0.3; 1.3)$ 58%	Operation time (min)	MD	1	19	26 (17; 36)	8	8370	13 (5.4; 20)	6704	53.5	1685	53.2	14 (7; 21)	%96	< 0.001
MD 1 19 3.2 (0.2; 6.2) 4 599 -0.4 (-1.4; 0.7) 334 17.2 284 16.9 -0.04 (-1.1; 1.0) 84% RR 1 19 0.9 (0.7; 1.2) 4 558 1.04 (0.96; 1.1) 277 191 (71%) 300 176 (59%) 1.03 (1.0; 1.1) 0% MD 1 19 2.7 (-3.7; 9.1) 4 390 0.48 (-0.3; 1.3) 218 7.9 191 8.0 0.5 (-0.3; 1.3) 58% MD 1 19 7.1 191 (71%) 300 176 (59%) 1.03 (1.0; 1.1) 0% MD 1 19 2.7 (-3.7; 9.1) 4 390 0.48 (-0.3; 1.3) 218 7.9 191 8.0 0.5 (-0.3; 1.3) 58%	Blood loss (mL)	MD	1	19	23 (-54; 100)	9	641	103 (17; 189)	305	351	355	204	92 (17; 171)	98%	0.02
· RR 1 19 0.9 (0.7; 1.2) 4 558 1.04 (0.96; 1.1) 277 191 (71%) 300 176 (59%) 1.03 (1.0; 1.1) 0% MD 1 19 2.7 (-3.7; 9.1) 4 390 0.48 (-0.3; 1.3) 218 7.9 191 8.0 0.5 (-0.3; 1.3) 58% MD 1 19 71 (14; 128) 2 210 7.8 (-2.7; 18.3) 133 63.2 96 50.4 13 (-3.2; 30) 73%	Time to union (weeks)	MD	1	19	3.2 (0.2; 6.2)	4	599	-0.4(-1.4;0.7)	334	17.2	284	16.9	-0.04(-1.1;1.0)	84%	0.94
MD 1 19 2.7 (-3.7; 9.1) 4 390 0.48 (-0.3; 1.3) 218 7.9 191 8.0 0.5 (-0.3; 1.3) 58% MD 1 19 71 (14; 128) 2 210 7.8 (-2.7; 18.3) 133 63.2 96 50.4 13 (-3.2; 30) 73%	Good quality of reduc- tion	RR	-	19	0.9 (0.7; 1.2)	4	558	1.04 (0.96; 1.1)	277	191 (71%)	300	176 (59%)	1.03 (1.0; 1.1)	%0	0.46
MD 1 19 71 (14; 128) 2 210 7.8 (-2.7; 18.3) 133 63.2 96 50.4 13 (-3.2; 30) 73%	Hospital stay (days)	MD	1	19	2.7 (-3.7; 9.1)	4	390	0.48(-0.3; 1.3)	218	7.9	191	8.0	0.5 (-0.3; 1.3)	58%	0.19
	Fluoroscopy time (s)	MD	1	19	71 (14; 128)	2	210	7.8 (-2.7; 18.3)	133	63.2	96	50.4	13 (-3.2; 30)	73%	0.12

🖄 Springer

EM extramedullary, IM intramedullary, MD mean difference, OM outcome measure, RCTs randomised controlled trials, RR risk ratio, x not reported




Fig. 2 Forrest plot for Harris hip score after extramedullary versus intramedullary fixation of stable trochanteric fractures. *IV* inverse variance, *RCT* randomized controlled trial, *SD* standard deviation




Fig. 3 Forrest plot of 1-year pain score after extramedullary versus intramedullary fixation of stable trochanteric fractures

1-year mortality (RR 0.98, CI 0.61–1.56, $l^2 = 0\%$, p = 0.92, OR4, Fig. 9) [19, 40].

Surgical outcomes

There was a significantly longer operation time (9 studies, Fig. 10) for extramedullary fixation, with a mean of 53.5 min in 6704 patients versus 53.2 min in 1685 patients in the intramedullary group (MD 14.1, CI 6.98–21.29, $I^2 = 96\%$, p < 0.001) [18, 19, 28, 29, 35, 39–41, 43]. Operative blood loss (7 studies, Fig. 11) in the extramedullary group was significantly higher as well, with a mean of 351 mL in 305 patients versus a mean of 204 mL in 355 patients in the intramedullary group (MD 92.30, CI 13.49–171.12, $I^2 = 98\%$, p = 0.02) [18, 19, 29, 35, 39, 40, 43].

No significant differences between the groups were found in the other surgical outcomes or operation characteristics: time to radiological union (MD -0.04, CI -1.10 to 1.02, $I^2 = 84\%$, p = 0.94, OR4, Fig. 10) [19, 29, 35, 38, 39], good quality of reduction (RR 1.03, CI 0.95–1.11, $I^2 = 0\%$, p = 0.46, OR4, Fig. 11) [19, 35, 38, 40, 41], hospital stay (MD 0.50, CI -0.25 to 1.25, $I^2 = 48\%$, p = 0.19, Online Resource 4, Fig. 12) [19, 35, 39, 41, 43], or fluoroscopy time (MD 13.12, CI -3.28 to 29.52, $I^2 = 73\%$, p = 0.12, Online Resource 4, Fig. 13) [19, 35, 41].

Only two studies reported data on hospital or surgeryrelated costs [41, 43]. Due to differences in included cost variables, no pooled effect could be calculated. None of the included studies reported data on cost-effectiveness.

	Extramed	-	Intramed	-		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	l Year	M-H, Random, 95% Cl
1.4.1 RCTs								
Ovesen et al. (2006)	0	17	4	23	0.9%	0.15 [0.01, 2.58]	2006	
Zou et al. (2009)	1	52	0	42	0.7%	2.43 [0.10, 58.25]	2009	
Parker et al. (2017)	3	83	1	87	1.4%	3.14 [0.33, 29.63]	2017	
Subtotal (95% CI)		152		152	2.9%	1.13 [0.16, 7.96]		
Total events	4		5					
Heterogeneity: Tau ² = 1.05; Cł	ni² = 3.08, df	= 2 (P =	0.21); l ² =	35%				
Test for overall effect: Z = 0.13	8 (P = 0.90)							
1.4.2 Observational studies								
Tian et al. (2010)	0	20	1	38	0.7%	0.62 [0.03, 14.54]	2010	
Matre et al. (2013)	189	6355	60	1288	27.7%	0.64 [0.48, 0.85]	2013	-
Yu et al. (2016)	15	112	7	110	7.8%	2.10 [0.89, 4.96]	2016	+- -
Talmac et al. (2019)	10	130	5	73	5.7%	1.12 [0.40, 3.16]	2019	
Van der Sijp et al. (2021)	2	32	4	94	2.5%	1.47 [0.28, 7.64]	2021	
Alessio-Mazzola et al. (2022)	0	44	0	41		Not estimable	2022	
Gronhaug et al (2022)	159	4811	67	2030	27.9%	1.00 [0.76, 1.33]	2022	+
Pyrhonen et al (2022)	104	3733	50	1722	24.8%	0.96 [0.69, 1.34]	2022	
Subtotal (95% CI)		15237		5396	97.1%	0.94 [0.71, 1.23]		◆
Total events	479		194					
Heterogeneity: Tau ² = 0.05; Cł	ni² = 10.61, d	lf = 6 (P :	= 0.10); l ² =	= 43%				
Test for overall effect: Z = 0.47	' (P = 0.64)							
Total (95% CI)		15389		5548	100.0%	0.94 [0.72, 1.23]		
Total events	483		199					
Heterogeneity: Tau ² = 0.05; Cł	ni² = 13.72, d	lf = 9 (P :	= 0.13); l² =	= 34%				
Test for overall effect: Z = 0.42		,	,,					0.01 0.1 1 10 10 Favors extramedullary Favors intramedullary
Test for subgroup differences:	· ,	df = 1 (P	= 0.85), l ²	= 0%				Favors extramedullary Favors intramedullary

Fig. 4 Forrest plot of reoperation rate after extramedullary versus intramedullary fixation of stable trochanteric fractures. *M*–*H* Mantel–Haen-szel, *RCT* randomized controlled trial, *SD* standard deviation




Fig. 5 Forrest plot of non-union rate after extramedullary versus intramedullary fixation of stable trochanteric fractures

Discussion

This systematic review and meta-analysis compared extramedullary and intramedullary fixation for stable twopart trochanteric fractures (AO 31-A1). No differences between fixation groups were found in functional outcomes and complications. Duration of surgery and intraoperative blood loss were found to be statically different between fixation groups, in favor of intramedullary fixation, though with a high level of heterogeneity.

	Extramedu	Illary	Intramedu	ullary		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI Ye	ar M-H, Random, 95% Cl
1.6.1 RCTs							
Pajarinen et al. (2005)	1	26	1	21	4.1%	0.81 [0.05, 12.16] 200	05
Ovesen et al. (2006)	0	17	2	23	3.4%	0.27 [0.01, 5.22] 200	06
Zou et al. (2009)	0	52	0	42		Not estimable 200	09
Parker et al. (2017) Subtotal (95% CI)	2	83 178	0	87 173	3.3% 10.9%	5.24 [0.26, 107.51] 20 ⁻ 1.01 [0.19, 5.36]	17
Total events	3		3				
Heterogeneity: Tau ² = 0.00;	Chi ² = 1.94,	df = 2 (P = 0.38); I	² = 0%			
Test for overall effect: Z = 0.	.01 (P = 0.99	9)					
1.6.2 Observational studie	s						
Tian et al. (2010)	0	20	1	38	3.0%	0.62 [0.03, 14.54] 20 ⁻	10
Andruszkow et al. (2012)	3	101	0	5	3.7%	0.41 [0.02, 7.09] 20	12
Crespo et al. (2012)	2	125	1	54	5.4%	0.86 [0.08, 9.33] 20	12
Matre et al. (2013)	17	6355	7	1288	39.4%	0.49 [0.20, 1.18] 20 ⁻	13
Yu et al. (2016)	3	112	1	110	6.0%	2.95 [0.31, 27.89] 20 ⁻	16
Cho et al. (2016)	1	113	1	81	4.0%	0.72 [0.05, 11.29] 20 ⁻	
Mohan et al. (2019)	0	24	1	30	3.0%	0.41 [0.02, 9.71] 20 ⁻	
Talmac et al. (2019)	7	130	5	73	24.6%	0.79 [0.26, 2.39] 20	19
Subtotal (95% CI)		6980		1679	89.1%	0.66 [0.37, 1.18]	\bullet
Total events	33		17				
Heterogeneity: Tau ² = 0.00;	Chi ² = 2.50,	df = 7 (P = 0.93); I	² = 0%			
Test for overall effect: Z = 1.	.39 (P = 0.16	5)					
Total (95% CI)		7158		1852	100.0%	0.69 [0.40, 1.20]	◆
Total events	36		20				
Heterogeneity: Tau ² = 0.00; Test for overall effect: Z = 1. Test for subgroup difference	.31 (P = 0.19	9)					0.01 0.1 1 10 100 Favors extramedullary Favors intramedullary

Fig. 6 Forrest plot of cut-out rate after extramedullary versus intramedullary fixation of stable trochanteric fractures

	Extramed	ullary	Intramed	ullary		Risk Ratio			Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	l Year		M-H, Random, 95% CI
1.7.1 RCTs									
Zou et al. (2009)	0	52	0	42		Not estimable	2009		
Parker et al. (2017)	0	83	0	87		Not estimable	2017		
Subtotal (95% CI)		135		129		Not estimable			
Total events	0		0						
Heterogeneity: Not app	licable								
Test for overall effect: I	Not applicab	le							
1.7.2 Observational st	tudies								
Matre et al. (2013)	10	6355	6	1288	45.7%	0.34 [0.12, 0.93]	2013		
Yu et al. (2016)	5	112	1	110	32.3%	4.91 [0.58, 41.36]	2016		
Talmac et al. (2019)	1	130	0	73	22.0%	1.69 [0.07, 41.07]	2019		
Subtotal (95% CI)		6597		1471	100.0%	1.14 [0.16, 8.18]			
Total events	16		7						
Heterogeneity: Tau ² =	1.94; Chi ² =	5.83, df	= 2 (P = 0.	05); I ² =	66%				
Test for overall effect: 2	Z = 0.13 (P =	= 0.89)							
Total (95% CI)		6732		1600	100.0%	1.14 [0.16, 8.18]			
Total events	16		7						
Heterogeneity: Tau ² =	1.94; Chi² =	5.83, df	= 2 (P = 0.	05); l² =	66%				
Test for overall effect: 2	Z = 0.13 (P =	= 0.89)						0.01	0.1 1 10 10 Favours extramedullary Favours intramedullary
Test for subgroup differ	rences: Not	applicab	le						r avours exitameduliary r avours intrameduliary

Fig. 7 Forrest plot of peri-implant fracture rate after extramedullary versus intramedullary fixation of stable trochanteric fractures

This is the first systematic review and meta-analysis that restricted the evaluation of treatment effect, in presentday devices, to patients with only stable two-part trochanteric fractures. It includes a substantially larger number of patients than all previous meta-analyses [9, 14, 21, 22, 45, 46]. The most recent Cochrane review, by Lewis et al. [45], on RCTs and 'RCT-like' cohort studies published up to July 2020 compared EM and IM fixation for a combination of AO A1-A3 fractures. In the only stratified analysis on A1 fractures, and in accordance with the current study's data, it found no differences between fixation groups for reoperation. For all combined fractures, it found no difference in reoperation, mortality, and several functional outcomes. Contrary to this review, it did find an increased risk of many complications including non-union, both superficial and deep infection, cut-out and implant failure for extramedullary devices.

	Extramed	lullary	Intramed	ullary		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
1.8.1 RCTs								
Ovesen et al. (2006)	0	17	2	23	0.8%	0.27 [0.01, 5.22]	2006	
Parker et al. (2017)	3	83	0	87	0.9%	7.33 [0.38, 139.84]	2017	
Subtotal (95% CI)		100		110	1.7%	1.41 [0.05, 36.45]		
Total events	3		2					
Heterogeneity: Tau ² = 3.23; Ch	i² = 2.42, df	= 1 (P =	0.12); I ² =	59%				
Test for overall effect: Z = 0.21	(P = 0.84)							
1.8.2 Observational studies								
Tian et al. (2010)	0	20	1	38	0.8%	0.62 [0.03, 14.54]	2010	· · · · · · · · · · · · · · · · · · ·
Matre et al. (2013)	113	6355	34	1288	34.0%	0.67 [0.46, 0.98]	2013	
Cho et al. (2016)	3	113	1	81	1.5%	2.15 [0.23, 20.30]	2016	
Pyrhonen et al (2022)	58	3675	33	1694	29.3%	0.81 [0.53, 1.24]	2022	
Gronhaug et al (2022)	92	4811	34	2030	32.8%	1.14 [0.77, 1.69]	2022	
Alessio-Mazzola et al. (2022)	0	44	0	41		Not estimable	2022	
Subtotal (95% CI)		15018		5172	98.3%	0.86 [0.67, 1.10]		•
Total events	266		103					
Heterogeneity: Tau ² = 0.01; Ch	i² = 4.40, df	= 4 (P =	0.35); l ² =	9%				
Test for overall effect: Z = 1.19	(P = 0.24)							
Total (95% CI)		15118		5282	100.0%	0.87 [0.66, 1.15]		•
Total events	269		105					
Heterogeneity: Tau ² = 0.02; Ch	i² = 7.05, df	= 6 (P =	0.32); l ² =	15%			F	01 0.1 1 10 100
Test for overall effect: Z = 0.99	(P = 0.32)	,					0.	01 0.1 1 10 100 Favors extramedullary Favors intramedullary
Test for subgroup differences: 0	Chi ² = 0.09,	df = 1 (P	= 0.77), l ²	= 0%				r avors extramedullary Favors intramedullary

Fig. 8 Forrest plot of conversion to prosthesis rate after extramedullary versus intramedullary fixation of stable trochanteric fractures

	Extramed		Intramed			Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	Year	M-H, Random, 95% Cl
1.9.1 RCTs								
Zou et al. (2009)	1	52	0	42	5.5%	2.43 [0.10, 58.25]	2009	
Subtotal (95% CI)		52		42	5.5%	2.43 [0.10, 58.25]		
Total events	1		0					
Heterogeneity: Not applicable								
Test for overall effect: Z = 0.55 ((P = 0.58)							
1.9.2 Observartional studies								
Tian et al. (2010)	0	20	1	38	5.5%	0.62 [0.03, 14.54]	2010	· · · · · · · · · · · · · · · · · · ·
Matre et al. (2013)	54	6355	10	1288	43.2%	1.09 [0.56, 2.14]	2013	
Cho et al. (2016)	4	113	2	81	16.1%	1.43 [0.27, 7.64]	2016	-
Yu et al. (2016)	1	112	1	110	7.0%	0.98 [0.06, 15.51]	2016	
Talmac et al. (2019)	1	130	0	73	5.4%	1.69 [0.07, 41.07]	2019	
Van der Sijp et al. (2021)	8	32	1	94	11.8%	23.50 [3.06, 180.69]	2021	→
Alessio-Mazzola et al. (2022)	1	44	0	41	5.5%	2.80 [0.12, 66.85]	2022	
Subtotal (95% CI)		6806		1725	94.5%	1.84 [0.75, 4.47]		
Total events	69		15					
Heterogeneity: Tau ² = 0.41; Chi	² = 8.61, df =	= 6 (P =	0.20); l ² = 3	30%				
Test for overall effect: Z = 1.34 ((P = 0.18)							
Total (95% CI)		6858		1767	100.0%	1.78 [0.82, 3.86]		
Total events	70		15					
Heterogeneity: Tau ² = 0.25; Chi ²	² = 8.70, df :	= 7 (P =	0.27); l ² = 2	20%			H	
Test for overall effect: Z = 1.45 ((0.01 0.1 1 10 100
Test for subgroup differences: C		df = 1 (P	= 0.87), l ²	= 0%				Favours extramedullary Favours intramedullary

Fig.9 Forrest plot of implant/fixation failure rate after extramedullary versus intramedullary fixation of stable trochanteric fractures

Intramedullary devices were associated with an increased intra- and post-operative periprosthetic fracture rate. The differences between this Cochrane review and our metaanalysis can largely be explained by the absence of several recently published large cohort studies, its combination of both stable, and unstable fractures, and inclusion of older studies with a relatively higher rate of complications.

Another review by Wessels et al. [21], comparing SHS vs IMN for AO A1-A3 trochanteric fractures, also found no

significant differences between fixation devices in the A1 fracture subgroup. Wessels et al. only described a combination of major complications and, specifically, non-union. Both Lewis et al. and Wessels et al. did not include surgical outcomes or operation characteristics and also included pathological fractures.

Older reviews by Parker et al. [46] and Jones et al. [14] studied fixation of all types of trochanteric fractures by cephalomedullary nail or sliding hip screw. As opposed to




Fig. 10 Forrest plot of mean operation time in minutes after extramedullary versus intramedullary fixation of stable trochanteric fractures




Fig. 11 Forrest plot of mean blood loss in milliliters after extramedullary versus intramedullary fixation of stable trochanteric fractures

the current meta-analysis and review by Wessels et al., they reported a significantly higher number of post- and intraoperative femoral fractures and higher reoperation rate for patients treated with a cephalomedullary nail. Both did not provide a stratified analysis for type of fracture. The difference between Jones et al., our findings and other recent reviews is likely caused by the fact that it included older studies, from the earlier days of intramedullary fixation. Since then, device quality, design and surgical experience with intramedullary devices have greatly improved. Where older research advised against the use of intramedullary fixation, current data on clinical and functional outcomes do not warrant any statement on the preferred type of device from a clinical perspective.

Interpretation of results

This meta-analysis found that only the duration of surgery and intra-operative blood loss to be statistically significantly in favor of intramedullary fixation. These results should be interpreted with care. The level of heterogeneity of effects across the studies was over 90% with large differences in mean operation time or blood loss (e.g. a range of 25.6–136 min for extramedullary fixation [18, 19]). This large variety may partly be explained by differences in surgery protocols, device used, experience of surgeons, the small number of inclusions, and inclusion or exclusion of anesthesia times across the included studies. The largest study by Matre et al. [28], with 7643 patients, and arguably the best sample size for this comparison, found no significant difference in operation time. The only other review reporting duration of surgery, by Parker et al. [46], included studies all conducted before the year 2005 and concluded that no definitive conclusion could be drawn because of limited data.

As current literature shows no differences between intra- and extramedullary fixation in functional outcomes or complications, it is tempting to conclude that surgeons could use either type of device. However, the difference in device costs should also be considered in this decision. Extramedullary fixation or more specifically dynamic/sliding hip screw is most likely the most cost-effective implant [47, 48]. Intramedullary devices can cost well over \$1000 more than extramedullary options with, as demonstrated by this review, the same surgical and clinical results for stable fractures. More expensive devices, such as PFNA, should be avoided when enough surgical expertise with extramedullary devices exists. This financial argument is also used in the Dutch Guideline for treatment of proximal femoral fractures and NICE guideline, as an argument for usage of extramedullary devices when clear evidence for superiority is absent [23, 24].

Some limitations should be considered when interpreting the results of this study: First, in every meta-analysis, there is a chance of publication bias, however, the funnel plots show no clear indication for one-sided publication for the included variables. The large majority of patients (>98%) included in this study came from observational studies resulting in a larger risk of selection bias. Many of the studied variables have a moderate-to-high level of heterogeneity between studies. Part of this could be explained by random chance and can be corrected for by using random effect models. Another part could be explained by the (small) differences in devices used, different moments in time studies were conducted, differences in study populations (e.g. age, fracture type prevalence, and inclusion of patients with concomitant injuries), and international differences between included studies. Most of the included RCTs and to a lesser degree, observational studies appear underpowered or only adequately powered for the total group of combined stable and unstable trochanteric femoral fractures. As many of the studied outcomes and complications are rare, and occur at rates of 1% or lower, studies are often not adequately powered to study these outcomes for a restricted group of stable fractures. A combination of heterogeneity and low power could conceal treatment effects that now seem insignificant. Although the clinical relevance of these effects may be questionable. Larger and adequately powered RCTs or high-quality prospective observational studies comparing extramedullary and intramedullary fixation in, specifically, stable trochanteric femoral fractures are needed to provide a definitive answer to the question of superiority for treatment for stable trochanteric fractures. Considering the low frequency of complications and sparsity of data on functional outcome and patient reported outcomes, future research should focus on both functional and quality of life data, and provide a large scale cost-effectiveness analysis.

Conclusion

There are no meaningful differences in complications, surgical-, or functional outcomes between intramedullary and extramedullary fixation of stable two-part trochanteric femoral (AO type 31-A1) fractures. Both treatment options result in good outcomes and few complications. As outcomes do not differ, costs should be taken into account when considering devices. Therefore, the use of extramedullary devices should be advised when enough surgical expertise with these devices is available. Future research should focus on (functional) outcomes for individual fracture AO type A1–A3 subgroups, and cost-effectivity of treatment and (medical) decision making for both techniques.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00402-023-04902-1.

Acknowledgements STABLE-HIP Study Group: Taco Gosens, MD PhD, Department of Orthopedics, Elisabeth-TweeSteden Hospital (ETZ), Tilburg, The Netherlands; Johannes H. Hegeman, MD PhD, Department of Surgery, Zorg Groep Twente (ZGT), Almelo, The Netherlands; Suzanne Polinder, PhD, Department of Public Health, Erasmuc MC, Rotterdam, The Netherlands; Rudolf W. Poolman, MD PhD, Department of Orthopedics, OLVG Hospital, Amsterdam, The Netherlands; Hanna C. Willems, MD PhD, Department of Geriatrics, Amsterdam University Medical Center, Amsterdam, The Netherlands; Rutger G. Zuurmond, MD PhD, Department of Orthopedics, Isala Hospital, Zwolle, The Netherlands

Author contributions The idea for this review and meta-analysis was conceived by PJ, MHJV, and EMML. Literature search and data collection was performed by LHTN and ACP, under supervision of MLZ, SAIL, and EMML. Statistical analysis was performed by MLZ, LHTN, and ACP, under supervision of EMML. The manuscript was drafted by MLZ, LHTN, and ACP. All authors critically revised the manuscript and approved the final version.

Funding The authors did not receive support from any organization for the submitted work.

Data availability All data used in this meta-analysis were published in previous literature. Specific information, on the data used or the analysis performed, is available upon request from the corresponding author.

Declarations

Conflict of interest The authors have no competing interests to declare that are relevant to the content of this article.

Ethical approval This systematic review and meta-analysis did not require approval from the local medical research ethics committee.

Informed consent This systematic review and meta-analysis did not require informed consent.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

- Amin S, Achenbach SJ, Atkinson EJ, Khosla S, Melton LJ 3rd (2014) Trends in fracture incidence: a population-based study over 20 years. J Bone Miner Res 29(3):581–589. https://doi.org/ 10.1002/jbmr.2072
- Collaborators GBDF (2021) Global, regional, and national burden of bone fractures in 204 countries and territories, 1990– 2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet Healthy Longev 2(9):e580–e592. https:// doi.org/10.1016/S2666-7568(21)00172-0
- 3. Tsuda T (2017) Epidemiology of fragility fractures and fall prevention in the elderly: a systematic review of the literature. Curr Orthop Pract 28(6):580–585. https://doi.org/10.1097/BCO. 000000000000563
- Adeyemi A, Delhougne G (2019) Incidence and economic burden of intertrochanteric fracture: a medicare claims database analysis. JB JS Open Access 4(1):e0045. https://doi.org/10. 2106/JBJS.OA.18.00045
- Kanters TA, van de Ree CLP, de Jongh MAC, Gosens T, Hakkaart-van RL (2020) Burden of illness of hip fractures in elderly Dutch patients. Arch Osteoporos 15(1):11. https://doi.org/10. 1007/s11657-019-0678-y
- Meinberg EG, Agel J, Roberts CS, Karam MD, Kellam JF (2018) Fracture and dislocation classification compendium-2018. J Orthop Trauma 32(Suppl 1):S1–S170. https:// doi.org/10.1097/BOT.00000000001063
- (DHFA) DHFA (2019) DHFA report 2019: Dutch Instute for Clinical Auditing (DICA). https://dica.nl/jaarrapportage-2019/ dhfa
- Kaplan K, Miyamoto R, Levine BR, Egol KA, Zuckerman JD (2008) Surgical management of hip fractures: an evidence-based review of the literature. II: intertrochanteric fractures. J Am Acad Orthop Surg 16(11):665–673. https://doi.org/10.5435/ 00124635-200811000-00007
- Zhang WQ, Sun J, Liu CY, Zhao HY, Sun YF (2018) Comparing the intramedullary nail and extramedullary fixation in treatment of unstable intertrochanteric fractures. Sci Rep 8(1):2321. https://doi.org/10.1038/s41598-018-20717-2
- Schipper IB, Marti RK, van der Werken C (2004) Unstable trochanteric femoral fractures: extramedullary or intramedullary fixation. Review of literature. Injury 35(2):142–151. https://doi. org/10.1016/s0020-1383(03)00287-0

- Forte ML, Virnig BA, Eberly LE, Swiontkowski MF, Feldman R, Bhandari M et al (2010) Provider factors associated with intramedullary nail use for intertrochanteric hip fractures. J Bone Jt Surg Am 92(5):1105–1114. https://doi.org/10.2106/ JBJS.I.00295
- Anglen JO, Weinstein JN, American Board of Orthopaedic Surgery Research C (2008) Nail or plate fixation of intertrochanteric hip fractures: changing pattern of practice. A review of the American Board of Orthopaedic Surgery Database. J Bone Jt Surg Am. 90(4):700–707. https://doi.org/10.2106/JBJS.G.00517
- Rogmark C, Spetz CL, Garellick G (2010) More intramedullary nails and arthroplasties for treatment of hip fractures in Sweden. Acta Orthop 81(5):588–592. https://doi.org/10.3109/17453674. 2010.506631
- Jones HW, Johnston P, Parker M (2006) Are short femoral nails superior to the sliding hip screw? A meta-analysis of 24 studies involving 3,279 fractures. Int Orthop 30(2):69–78. https://doi. org/10.1007/s00264-005-0028-0
- Parker MJ, Handoll HH, Bhonsle S, Gillespie WJ (2000) Condylocephalic nails versus extramedullary implants for extracapsular hip fractures. Cochrane Database Syst Rev (2):CD000338. https://doi.org/10.1002/14651858.CD000338
- Parker MJ, Handoll HH, Chinoy MA (2001) Extramedullary fixation implants for extracapsular hip fractures. Cochrane Database Syst Rev (2):CD000339. https://doi.org/10.1002/14651 858.CD000339
- Parker MJ (2017) Sliding hip screw versus intramedullary nail for trochanteric hip fractures; a randomised trial of 1000 patients with presentation of results related to fracture stability. Injury 48(12):2762–2767. https://doi.org/10.1016/j.injury.2017. 10.029
- Mohan H, Kumar P (2019) Surgical treatment of type 31–A1 two-part intertrochanteric femur fractures: is proximal femoral nail superior to dynamic hip screw fixation? Cureus 11(2):e4110. https://doi.org/10.7759/cureus.4110
- Talmac MA, Gorgel MA, Armagan R, Sonmez MM, Ozdemir HM (2019) Examining implant superiority in the treatment of simple pertrochanteric fractures of the proximal femur in elderly patients. Yasli hastalarda proksimal femur basit pertrokanterik kiriklarin tedavisinde hangi implant ustundur? Ulus Travma Acil Cerrahi Derg 25(4):410–6. https://doi.org/10.14744/tjtes.2019.21270
- Singh NK, Sharma V, Trikha V, Gamanagatti S, Roy A, Balawat AS et al (2019) Is PFNA-II a better implant for stable intertrochanteric fractures in elderly population? A prospective randomized study. J Clin Orthop Trauma 10(Suppl 1):S71–S76. https://doi. org/10.1016/j.jcot.2019.02.004
- Wessels JO, Bjarnesen MP, Erichsen JL, Palm H, Gundtoft PH, Viberg B (2022) Sliding hip screw vs intramedullary nail for AO/ OTA31A1-A3: a systematic review and meta-analysis. Injury 53(3):1149–1159. https://doi.org/10.1016/j.injury.2021.12.034
- 22. Bhandari M, Schemitsch E, Jonsson A, Zlowodzki M, Haidukewych GJ (2009) Gamma nails revisited: gamma nails versus compression hip screws in the management of intertrochanteric fractures of the hip: a meta-analysis. J Orthop Trauma 23(6):460–464. https://doi.org/10.1097/BOT.0b013e318162f67f
- 23. Heelkunde MwNOVNVv (2016) Behandeling pertrochantere fracturen: Federatie Medisch Specialisten; [updated 1 september 2016]. https://richtlijnendatabase.nl/richtlijn/proximale_femur fracturen/pertrochantere_femurfractuur/behandeling_pertrochan tere_fracturen.html
- (NICE) NIfHaCE (2020) National Institute for Health and Care Excellence: Guidelines, Hip fracture management. ed2017. NBK553768 [bookaccession]
- 25. Mellema JJ, Janssen S, Schouten T, Haverkamp D, van den Bekerom MPJ, Ring D et al (2021) Intramedullary nailing versus sliding hip screw for A1 and A2 trochanteric hip fractures. Bone Jt

J 103-B(4):775-781. https://doi.org/10.1302/0301-620X.103B. BJJ-2020-1490.R1

- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:// doi.org/10.1136/bmj.n71
- 27. Sevinc HF, Cirpar M, Canbeyli ID, Daglar B, Oktas B, Durusoy S (2020) Comparison of functional outcomes in patients fixed with dynamic hip screw and proximal femur nail-anti-rotation in A1 and A2 type intertrochanteric femur fractures A1 ve A2 tipi femur intertrokanterik kiriklarinda kayan kalca vidasi ve proksimal femur civisi-antirotasyon ile tespit sonrasi hastalarin fonksiyonel sonuclarinin karsilastirilmasi. Ulus Travma Acil Cerrahi Derg 26(5):811–7. https://doi.org/10.14744/tjtes.2020.39888.
- Matre K, Havelin LI, Gjertsen JE, Espehaug B, Fevang JM (2013) Intramedullary nails result in more reoperations than sliding hip screws in two-part intertrochanteric fractures. Clin Orthop Relat Res 471(4):1379–1386. https://doi.org/10.1007/ s11999-012-2728-2
- Cho HM, Lee K (2016) Clinical and functional outcomes of treatment for type A1 intertrochanteric femoral fracture in elderly patients: comparison of dynamic hip screw and proximal femoral nail antirotation. Hip Pelvis 28(4):232–242. https://doi.org/10.5371/hp.2016.28.4.232
- Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73(9):712–716. https://doi.org/10.1046/j.1445-2197.2003.02748.x
- Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:14898. https://doi.org/10.1136/ bmj.14898
- 32. Pajarinen J, Lindahl J, Michelsson O, Savolainen V, Hirvensalo E (2005) Pertrochanteric femoral fractures treated with a dynamic hip screw or a proximal femoral nail. A randomised study comparing post-operative rehabilitation. J Bone Jt Surg Br 87(1):76–81
- Ovesen O, Andersen M, Poulsen T, Nymark T, Overgaard S, Rock ND (2006) The trochanteric gamma nail versus the dynamic hip screw: a prospective randomised study. One-year follow-up of 146 intertrochanteric fractures. Hip Int 16(4):293–298. https://doi.org/ 10.5301/hip.2008.2820
- Zou J, Xu Y, Yang H (2009) A comparison of proximal femoral nail antirotation and dynamic hip screw devices in trochanteric fractures. J Int Med Res 37(4):1057–1064. https://doi.org/10. 1177/147323000903700410
- 35. Tao R, Lu Y, Xu H, Zhou ZY, Wang YH, Liu F (2013) Internal fixation of intertrochanteric hip fractures: a clinical comparison of two implant designs. ScientificWorldJournal. 2013:834825. https://doi.org/10.1155/2013/834825
- 36. Andruszkow H, Frink M, Fromke C, Matityahu A, Zeckey C, Mommsen P et al (2012) Tip apex distance, hip screw placement, and neck shaft angle as potential risk factors for cut-out failure of hip screws after surgical treatment of intertrochanteric fractures. Int Orthop 36(11):2347–2354. https://doi.org/10.1007/ s00264-012-1636-0
- Crespo E, Galvez J, Tenias JM, Cano I, Crespo R, Palacios V (2012) A comparative study between gamma nail and percutaneous compression plating for the treatment of intertrochanteric hip fractures. Eur J Trauma Emerg Surg 38(4):443–449. https://doi. org/10.1007/s00068-012-0181-2

- 38. Yu W, Zhang X, Zhu X, Yu Z, Xu Y, Zha G et al (2016) Proximal femoral nails anti-rotation versus dynamic hip screws for treatment of stable intertrochanteric femur fractures: an outcome analyses with a minimum 4 years of follow-up. BMC Musculoskelet Disord 17:222. https://doi.org/10.1186/s12891-016-1079-7
- 39. Tian YYWZ (2018) Short-term follow-up of dynamic hip screw versus proximal femoral nail anti-rotation for type AO/OTA A1 intertrochanteric femoral fracture in older adults. Chin J Tissue Eng Res 23(12):1834–1839
- 40. van der Sijp MPL, de Groot M, Meylaerts SA, du Pre KJ, Verhage SM, Schipper IB et al (2021) High risks of failure observed for A1 trochanteric femoral fractures treated with a DHS compared to the PFNA in a prospective observational cohort study. Arch Orthop Trauma Surg. https://doi.org/10.1007/s00402-021-03824-0
- Alessio-Mazzola M, Traverso G, Coccarello F, Sanguineti F, Formica M (2022) Dynamic hip screw versus intramedullary nailing for the treatment of A1 intertrochanteric fractures: a retrospective, comparative study and cost analysis. Jt Dis Relat Surg 33(2):314–322. https://doi.org/10.52312/jdrs.2022.646
- 42. Gronhaug KML, Dybvik E, Matre K, Ostman B, Gjertsen JE (2022) Intramedullary nail versus sliding hip screw for stable and unstable trochanteric and subtrochanteric fractures : 17,341 patients from the Norwegian Hip Fracture Register. Bone Jt J 104-B(2):274–282. https://doi.org/10.1302/0301-620x.104b2. Bjj-2021-1078.R1
- 43. Pehlivanoglu T, Bayram S, Demirel M, Chodza M, Kocazeybek E, Salduz A et al (2021) Proximal femoral nailing versus dynamic hip screw in management of stable intertrochanteric femur fractures: a comparison of clinical and radiological outcomes. J Istanb Fac Med 84(4):514–520
- 44. Pyrhonen HS, Lagergren J, Wolf O, Bojan A, Mukka S, Moller M et al (2022) No difference in conversion rate to hip arthroplasty after intramedullary nail or sliding hip screw for extracapsular hip fractures: an observational cohort study of 19,604 individuals. J Bone Jt Surg Am. https://doi.org/10.2106/jbjs.22.00316
- Lewis SR, Macey R, Gill JR, Parker MJ, Griffin XL (2022) Cephalomedullary nails versus extramedullary implants for extracapsular hip fractures in older adults. Cochrane Database Syst Rev 1:CD000093. https://doi.org/10.1002/14651858.CD000093.pub6
- Parker MJ, Handoll HH (2010) Gamma and other cephalocondylic intramedullary nails versus extramedullary implants for extracapsular hip fractures in adults. Cochrane Database Syst Rev (9):CD000093. https://doi.org/10.1002/14651858.CD000093. pub5
- Swart E, Makhni EC, Macaulay W, Rosenwasser MP, Bozic KJ (2014) Cost-effectiveness analysis of fixation options for intertrochanteric hip fractures. J Bone Jt Surg Am 96(19):1612–1620. https://doi.org/10.2106/JBJS.M.00603
- Bohl DD, Basques BA, Golinvaux NS, Miller CP, Baumgaertner MR, Grauer JN (2014) Extramedullary compared with intramedullary implants for intertrochanteric hip fractures: thirty-day outcomes of 4432 procedures from the ACS NSQIP database. J Bone Jt Surg Am 96(22):1871–1877. https://doi.org/10.2106/JBJS.N. 00041

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.